Navigation Links
Science Fuels DNA Testing Controversy with Prejudicial Misquote
Date:4/3/2008

rshiping at the altar of randomized trials." John Concato, MD,

Yale University.

Genelex's Position:

-- Individuals have a right to learn their genotype and control who

accesses this confidential information.

-- Excessive regulation will impede the already slow adoption of DNA

testing in medication management.

-- There needs to be symmetry between the level of proof required for

technology adoption and the potential risk and cost benefit ratios.

-- A peer-developed rating system needs to be developed that describes

where a given test lies on the continuum of scientific knowledge

about the utility, acceptance and proof of that test as a tool for

informed decision-making.

Randomized trials are in progress that will add to our knowledge. In the meantime clinicians and patients who find this information useful should have access to it. Physicians don't prescribe without knowing the patient's age, sex, and medical history, and often CYP genetics are more important than all these factors combined.


'/>"/>
SOURCE Genelex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis New Headquarters
2. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
3. Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science
4. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
5. Bioscience Career Fair in North Carolina Expected to Attract Well Qualified Job Seekers
6. Bioscience Career Fair in San Francisco Projected to Break Job Seeker Attendance Records
7. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
8. ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
9. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
10. Derma Sciences Reports Fourth Quarter Year-End Results for 2007
11. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... The Cholangiocarcinoma Foundation (CCF), a ... duct cancer, announced today the first grant recipients ... , The Foundation has awarded 5 grants ... to raise awareness about cholangiocarcinoma and inspire innovative, ... opens new pathways for diagnosis and drug discovery ...
(Date:5/30/2015)... , May 30, 2015 CTI BioPharma ... International,s Bioscience business (NYSE: BAX ) today announced ... trial examining pacritinib for the treatment of myelofibrosis – ... Annual Meeting of the American Society of Clinical Oncology ... Ill. Pacritinib is an investigational oral multikinase ...
(Date:5/30/2015)... RARITAN, N.J. , May 30, 2015 /PRNewswire/ ... Phase 2 MMY2002 (SIRIUS) trial show treatment with ... antibody – achieved an overall response rate (ORR) ... by an independent review committee, in heavily pre-treated ... among the pre-specified subgroups based on age, prior ...
(Date:5/30/2015)... IRVING, Texas , May 30, 2015 /PRNewswire/ ... data from a study in which researchers identified ... of metachronous paired glioma tumors, indicating changes in ... study observing 19 patients was a subset of ... confirmed molecular heterogeneity of the cancer. These data ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... , CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. ... raise approximately $3.1 million in gross proceeds, before deducting placement agent ... of 9.5 million units, at a price of $0.33 per unit. ... and (ii) a warrant exercisable at any time on or after ...
... , OMAHA, Neb., Aug. 12 Transgenomic Inc. (OTC Bulletin Board: TBIO) announces ... Transgenomic Inc. Second Quarter 2009 Earnings Release, ... 2009 @ 5:00 p.m. Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , ... at the, address above., ...
... , , WALTHAM, Mass., ... research and advisory firms focusing on pharmaceutical and healthcare issues, ... share in second- and third-line therapy since last year,s analysis ... attributed to the publication of the ENHANCE trial which called ...
Cached Biology Technology:Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering 2Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering 3Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 3
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 28, 2015 Industry analyst firm n-tech ... report titled "Markets for Self-Healing Materials: 2015-2022." According to ... and vascular systems, biomaterials, relevant shape memory materials ... $2.7 billion by 2020. The report ... of smart materials. Other recent n-tech reports have included ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... For coffee lovers, the first cup of the morning is one ... grounds could eliminate one of the worst smells around sewer ... remove toxic gases from the air, scientists at The City College ... coffee grounds can sop up hydrogen sulfide gas, the chemical that ...
... DURHAM, N.H. Americans, knowledge of facts about the ... but this increase in knowledge has not translated into ... research from the Carsey Institute at the University of ... issues improved from 2006 to 2010, consistent with hopes ...
... Second Class? Confronting the Risks to U.S. ... Research Foruma unique interactive gathering of top policy ... agencies for health research, as well as nationally ... Two panels will each be followed by Q&A, ...
Cached Biology News:Carbonized coffee grounds remove foul smells 2Carsey Institute: Americans' knowledge of polar regions up, but not their concern 2World class to second class? Confronting the risks to US science and innovation 2